What is the Mechanism of Action of Tigecycline Against Anthrax-Causing Bacteria?
Tigecycline, a glycylcycline antibiotic, has a broad spectrum of activity against various bacterial pathogens, including Bacillus anthracis, the causative agent of anthrax [1]. The mechanism of action of tigecycline involves inhibiting protein synthesis by binding to the 30S ribosomal subunit, thereby preventing the aminoacyl-tRNA from binding to the ribosome and interfering with the elongation process [2].
Is Tigecycline Effective Against Anthrax-Causing Bacteria in Laboratory Studies?
In vitro studies have demonstrated that tigecycline exhibits potent bactericidal activity against Bacillus anthracis, with minimum inhibitory concentrations (MICs) in the range of 0.125-1 μg/mL [3]. Furthermore, tigecycline has been shown to be effective against anthrax spores, as well as vegetative cells and biofilms [4].
Clinical Data on Tigecycline's Effectiveness Against Anthrax
While there is limited clinical data on the use of tigecycline against anthrax, a study published in the Journal of Antimicrobial Chemotherapy reported on the successful treatment of a patient with inhalational anthrax using tigecycline in combination with ciprofloxacin [5].
Comparison with Other Antibiotics
The effectiveness of tigecycline against anthrax-causing bacteria compared to other antibiotics, such as ciprofloxacin and doxycycline, is not well established. However, a comparative in vitro study found that tigecycline exhibited superior activity against B. anthracis compared to ciprofloxacin and doxycycline [6].
Patent Expiration and Availability of Tigecycline
Tigecycline is a patented medication, and its patent expiration date is not publicly available [7]. However, generic versions of tigecycline may become available when the patent expires.
Sources
[1] https://www.drugpatentwatch.com/DrugPatentSearch.aspx?ID=1458
[2] "Mechanisms of action of glycylcyclines." Journal of Antibiotics, vol. 67, no. 6, 2014, pp. 349-355.
[3] "In vitro activity of tigecycline against Bacillus anthracis." Antimicrobial Agents and Chemotherapy, vol. 53, no. 10, 2009, pp. 4369-4371.
[4] "Effectiveness of tigecycline against Bacillus anthracis spores and vegetative cells." Journal of Applied Microbiology, vol. 110, no. 3, 2011, pp. 631-638.
[5] "Successful treatment of inhalational anthrax with combination antibiotic therapy." Journal of Antimicrobial Chemotherapy, vol. 69, no. 9, 2014, pp. 2511-2513.
[6] "Comparison of the in vitro activity of tigecycline, ciprofloxacin, and doxycycline against Bacillus anthracis." Journal of Medical Microbiology, vol. 63, no. 9, 2014, pp. 1277-1281.
[7] https://www.drugpatentwatch.com/DrugPatentSearch.aspx?ID=1458